What factors drove MRNA's EPS surge in early 2024?

Moderna's EPS experienced a surge in early 2024, primarily driven by several key factors:

1. **Revenue from Respiratory Franchise**: Moderna's respiratory franchise contributed significantly to the revenue, with sales expectations of around $4 billion for 2024. This was primarily due to the sales of their COVID-19 vaccine, which generated substantial income throughout 2023 and into 2024.
2. **Cost Management**: The company achieved a 27% reduction in costs compared to 2023, reflecting strategic cost initiatives and operational efficiencies. This cost management was a significant factor in the improved EPS.
3. **International Sales**: Moderna's international sales played a crucial role in boosting revenue. Despite the decline in international sales of COVID-19 vaccines, the company's focus on international markets, particularly in Europe, helped to offset the impact of declining COVID-19 vaccine sales in the U.S..

In conclusion, Moderna's EPS surge in early 2024 was driven by strong revenue from its respiratory franchise, effective cost management, and strategic focus on international markets.